Treatment of graft-versus-host disease with monoclonal antibodies and related fusion proteins

References

• Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature411(6835), 385–389 (2001).
   PubMed Web of Science ®Google Scholar
• Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet373(9674), 1550–1561 (2009).
   PubMed Web of Science ®Google Scholar
• Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu. Rev. Immunol.25, 139–170 (2007).
   PubMed Web of Science ®Google Scholar
• Wolff D, Steiner B, Hildebrandt G et al. Pharmaceutical and cellular strategies in prophylaxis and treatment of graft-versus-host disease. Curr. Pharm. Des.15(17), 1974–1997 (2009).
   PubMed Web of Science ®Google Scholar
• Martin PJ, Schoch G, Fisher L et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood76(8), 1464–1472 (1990).
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Mori M, Sanders J et al. Late complications of allogeneic and autologous marrow transplantation. Bone Marrow Transplant.10(Suppl. 1), 127–134 (1992).
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Agura E, Anasetti C et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin. Hematol.28(3), 250–259 (1991).
   PubMed Web of Science ®Google Scholar
• Filipovich AH, Weisdorf D, Pavletic S et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol. Blood Marrow Transplant.11(12), 945–956 (2005).
   PubMed Web of Science ®Google Scholar
• Petersdorf EW, Longton GM, Anasetti C et al. The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood86(4), 1606–1613 (1995).
   PubMed Web of Science ®Google Scholar
• Loiseau P, Busson M, Balere ML et al. HLA association with hematopoietic stem cell transplantation outcome: the number of mismatches at HLA-A, -B, -C, -DRB1, or -DQB1 is strongly associated with overall survival. Biol. Blood Marrow Transplant.13(8), 965–974 (2007).
   PubMed Web of Science ®Google Scholar
• Ratanatharathorn V, Nash RA, Przepiorka D et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood92(7), 2303–2314 (1998).
   PubMed Web of Science ®Google Scholar
• Anasetti C, Rybka W, Sullivan KM, Banaji M, Slichter SJ. Graft-v-host disease is associated with autoimmune-like thrombocytopenia. Blood73(4), 1054–1058 (1989).
   PubMed Web of Science ®Google Scholar
• MacMillan ML, Weisdorf DJ, Wagner JE et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol. Blood Marrow Transplant.8(7), 387–394 (2002).
   PubMed Web of Science ®Google Scholar
• Martin PJ, Schoch G, Fisher L et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood77(8), 1821–1828 (1991).
   PubMed Web of Science ®Google Scholar
• Cahn JY, Klein JP, Lee SJ et al. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood106(4), 1495–1500 (2005).
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Holler E. Adoptive immunotherapy with donor lymphocyte transfusions. Curr. Opin. Oncol.9(2), 139–145 (1997).
   PubMedGoogle Scholar
• Storb R, Rudolph RH, Thomas ED. Marrow grafts between canine siblings matched by serotyping and mixed leukocyte culture. J. Clin. Invest.50(6), 1272–1275 (1971).
   PubMed Web of Science ®Google Scholar
• Mills GB, Schmandt R, Gibson S et al. Transmembrane signaling by the interleukin-2 receptor: progress and conundrums. Semin. Immunol.5(5), 345–364 (1993).
   PubMedGoogle Scholar
• Anasetti C, Martin PJ, Hansen JA et al. A Phase I–II study evaluating the murine anti-IL-2 receptor antibody 2A3 for treatment of acute graft-versus-host disease. Transplantation50(1), 49–54 (1990).
   PubMed Web of Science ®Google Scholar
• Cuthbert RJ, Phillips GL, Barnett MJ et al. Anti-interleukin-2 receptor monoclonal antibody (BT 563) in the treatment of severe acute GVHD refractory to systemic corticosteroid therapy. Bone Marrow Transplant.10(5), 451–455 (1992).
   PubMed Web of Science ®Google Scholar
• Herbelin C, Stephan JL, Donadieu J et al. Treatment of steroid-resistant acute graft-versus-host disease with an anti-IL-2-receptor monoclonal antibody (BT 563) in children who received T cell-depleted, partially matched, related bone marrow transplants. Bone Marrow Transplant.13(5), 563–569 (1994).
   PubMed Web of Science ®Google Scholar
• Herve P, Wijdenes J, Bergerat JP et al. Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10). Blood75(4), 1017–1023 (1990).
   PubMed Web of Science ®Google Scholar
• Anasetti C, Hansen JA, Waldmann TA et al. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood84(4), 1320–1327 (1994).
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Kernan NA, Ippoliti C et al. Daclizumab, a humanized anti-interleukin-2 receptor α chain antibody, for treatment of acute graft-versus-host disease. Blood95(1), 83–89 (2000).
   PubMed Web of Science ®Google Scholar
• Perales MA, Ishill N, Lomazow WA et al. Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease. Bone Marrow Transplant.40(5), 481–486 (2007).
   PubMed Web of Science ®Google Scholar
• Willenbacher W, Basara N, Blau IW, Fauser AA, Kiehl MG. Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. Br. J. Haematol.112(3), 820–823 (2001).
   PubMed Web of Science ®Google Scholar
• Srinivasan R, Chakrabarti S, Walsh T et al. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis. Br. J. Haematol.124(6), 777–786 (2004).
   PubMed Web of Science ®Google Scholar
• Lee SJ, Zahrieh D, Agura E et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood104(5), 1559–1564 (2004).
   PubMed Web of Science ®Google Scholar
• Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet350(9086), 1193–1198 (1997).
   PubMed Web of Science ®Google Scholar
• Funke VA, de Medeiros CR, Setubal DC et al. Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist. Bone Marrow Transplant.37(10), 961–965 (2006).
   PubMed Web of Science ®Google Scholar
• Massenkeil G, Rackwitz S, Genvresse I, Rosen O, Dorken B, Arnold R. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant.30(12), 899–903 (2002).
   PubMed Web of Science ®Google Scholar
• Schmidt-Hieber M, Fietz T, Knauf W et al. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease. Br. J. Haematol.130(4), 568–574 (2005).
   PubMed Web of Science ®Google Scholar
• Edinger M, Hoffmann P, Ermann J et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat. Med.9(9), 1144–1150 (2003).
   PubMed Web of Science ®Google Scholar
• Ho VT, Zahrieh D, Hochberg E et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood104(4), 1224–1226 (2004).
   PubMed Web of Science ®Google Scholar
• Shaughnessy PJ, Bachier C, Grimley M et al. Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease. Biol. Blood Marrow Transplant.11(3), 188–193 (2005).
   PubMed Web of Science ®Google Scholar
• Alousi AM, Weisdorf DJ, Logan BR et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized Phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood114(3), 511–517 (2009).
   PubMed Web of Science ®Google Scholar
• Hale G. The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy3(3), 137–143 (2001).
   PubMed Web of Science ®Google Scholar
• Ratzinger G, Reagan JL, Heller G, Busam KJ, Young JW. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft–host interactions in transplantation. Blood101(4), 1422–1429 (2003).
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Zenz T, Winkler D et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J. Clin. Oncol.27(24), 3994–4001 (2009).
   PubMed Web of Science ®Google Scholar
• Kottaridis PD, Milligan DW, Chopra R et al.In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood96(7), 2419–2425 (2000).
   PubMed Web of Science ®Google Scholar
• Khouri IF, Albitar M, Saliba RM et al. Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics. Bone Marrow Transplant.33(8), 833–837 (2004).
   PubMed Web of Science ®Google Scholar
• Busca A, Locatelli F, Lovisone E et al. Treatment of severe refractory acute graft-versus-host disease of the gastrointestinal tract with Campath-1H. Biol. Blood Marrow Transplant.11(9), 734–736 (2005).
   PubMed Web of Science ®Google Scholar
• Carella AM, Beltrami G, Scalzulli PR, Carella AM Jr, Corsetti MT. Alemtuzumab can successfully treat steroid-refractory acute graft-versus-host disease (aGVHD). Bone Marrow Transplant.33(1), 131–132 (2004).
   PubMed Web of Science ®Google Scholar
• Gomez-Almaguer D, Ruiz-Arguelles GJ, del Carmen Tarin-Arzaga L et al. Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease. Biol. Blood Marrow Transplant.14(1), 10–15 (2008).
   PubMed Web of Science ®Google Scholar
• Schnitzler M, Hasskarl J, Egger M, Bertz H, Finke J. Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab. Biol. Blood Marrow Transplant.15(8), 910–918 (2009).
   PubMed Web of Science ®Google Scholar
• Wandroo F, Auguston B, Cook M, Craddock C, Mahendra P. Successful use of Campath-1H in the treatment of steroid refractory liver GvHD. Bone Marrow Transplant.34(3), 285–287 (2004).
   PubMed Web of Science ®Google Scholar
• Shapira MY, Resnick IB, Bitan M et al. Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report. Bone Marrow Transplant.36(12), 1097–1101 (2005).
   PubMed Web of Science ®Google Scholar
• Shapira MY, Resnick IB, Dray L et al. A new induction protocol for the control of steroid refractory/dependent acute graft versus host disease with alefacept and tacrolimus. Cytotherapy11(1), 61–67 (2009).
   PubMed Web of Science ®Google Scholar
• Toor AA, Stiff PJ, Nickoloff BJ, Rodriguez T, Klein JL, Gordon KB. Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activity. J. Dermatolog. Treat.18(1), 13–18 (2007).
   PubMed Web of Science ®Google Scholar
• Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N. Engl. J. Med.345(4), 248–255 (2001).
   PubMed Web of Science ®Google Scholar
• Bashir SJ, Maibach HI. Alefacept (Biogen). Curr. Opin. Investig. Drugs2(5), 631–634 (2001).
   PubMedGoogle Scholar
• Cooper JC, Morgan G, Harding S et al. Alefacept selectively promotes NK cell-mediated deletion of CD45R0+ human T cells. Eur. J. Immunol.33(3), 666–675 (2003).
   PubMed Web of Science ®Google Scholar
• Deeg HJ, Blazar BR, Bolwell BJ et al. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood98(7), 2052–2058 (2001).
   PubMed Web of Science ®Google Scholar
• Heslop HE, Benaim E, Brenner MK et al. Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1. Lancet346(8978), 805–806 (1995).
   PubMed Web of Science ®Google Scholar
• Macmillan ML, Couriel D, Weisdorf DJ et al. A Phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood109(6), 2657–2662 (2007).
   PubMed Web of Science ®Google Scholar
• Guo H, Majmudar G, Jensen TC, Biswas C, Toole BP, Gordon MK. Characterization of the gene for human EMMPRIN, a tumor cell surface inducer of matrix metalloproteinases. Gene220(1-2), 99–108 (1998).
   PubMed Web of Science ®Google Scholar
• Kinukawa T, Terasaki PI. Clonal deletion by a monoclonal antiblast antibody following primary mixed lymphocyte culture. Transplant P.17(1), 993–998 (1985).
   Web of Science ®Google Scholar
• Koch C, Staffler G, Huttinger R et al. T cell activation-associated epitopes of CD147 in regulation of the T cell response, and their definition by antibody affinity and antigen density. Int. Immunol.11(5), 777–786 (1999).
   PubMed Web of Science ®Google Scholar
• Norman DJ, Barry JM, Bennett WM et al. The use of OKT3 in cadaveric renal transplantation for rejection that is unresponsive to conventional anti-rejection therapy. Am. J. Kidney Dis.11(2), 90–93 (1988).
   PubMed Web of Science ®Google Scholar
• Buysmann S, Bemelman FJ, Schellekens PT, van Kooyk Y, Figdor CG, ten Berge IJ. Activation and increased expression of adhesion molecules on peripheral blood lymphocytes is a mechanism for the immediate lymphocytopenia after administration of OKT3. Blood87(1), 404–411 (1996).
   PubMed Web of Science ®Google Scholar
• Gleixner B, Kolb HJ, Holler E et al. Treatment of aGVHD with OKT3: clinical outcome and side-effects associated with release of TNF α. Bone Marrow Transplant.8(2), 93–98 (1991).
   PubMed Web of Science ®Google Scholar
• Hebart H, Ehninger G, Schmidt H et al. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies. Bone Marrow Transplant.15(6), 891–894 (1995).
   PubMed Web of Science ®Google Scholar
• Gratama JW, Jansen J, Lipovich RA, Tanke HJ, Goldstein G, Zwaan FE. Treatment of acute graft-versus-host disease with monoclonal antibody OKT3. Clinical results and effect on circulating T lymphocytes. Transplantation38(5), 469–474 (1984).
   PubMed Web of Science ®Google Scholar
• Knop S, Hebart H, Gscheidle H et al. OKT3 muromonab as second-line and subsequent treatment in recipients of stem cell allografts with steroid-resistant acute graft-versus-host disease. Bone Marrow Transplant.36(9), 831–837 (2005).
   PubMed Web of Science ®Google Scholar
• Knop S, Hebart H, Gratwohl A et al. Treatment of steroid-resistant acute GVHD with OKT3 and high-dose steroids results in better disease control and lower incidence of infectious complications when compared with high-dose steroids alone: a randomized multicenter trial by the EBMT Chronic Leukemia Working Party. Leukemia21(8), 1830–1833 (2007).
   PubMed Web of Science ®Google Scholar
• Carpenter PA, Appelbaum FR, Corey L et al. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood99(8), 2712–2719 (2002).
   PubMed Web of Science ®Google Scholar
• Carpenter PA, Lowder J, Johnston L et al. A Phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biol. Blood Marrow Transplant.11(6), 465–471 (2005).
   PubMed Web of Science ®Google Scholar
• Reddy P, Ferrara JL. Immunobiology of acute graft-versus-host disease. Blood Rev.17(4), 187–194 (2003).
   PubMed Web of Science ®Google Scholar
• Korngold R, Marini JC, de Baca ME, Murphy GF, Giles-Komar J. Role of tumor necrosis factor-α in graft-versus-host disease and graft-versus-leukemia responses. Biol. Blood Marrow Transplant.9(5), 292–303 (2003).
   PubMed Web of Science ®Google Scholar
• Vandenabeele P, Declercq W, Beyaert R, Fiers W. Two tumor-necrosis-factor receptors: structure and function. Trends Cell Biol.5(10), 392–399 (1995).
   PubMed Web of Science ®Google Scholar
• Choi SW, Kitko CL, Braun T et al. Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood112(4), 1539–1542 (2008).
   PubMed Web of Science ®Google Scholar
• Holler E, Kolb HJ, Moller A et al. Increased serum levels of tumor necrosis factor α precede major complications of bone marrow transplantation. Blood75(4), 1011–1016 (1990).
   PubMed Web of Science ®Google Scholar
• Herve P, Flesch M, Tiberghien P et al. Phase I–II trial of a monoclonal anti-tumor necrosis factor α antibody for the treatment of refractory severe acute graft-versus-host disease. Blood79(12), 3362–3368 (1992).
   PubMed Web of Science ®Google Scholar
• Kobbe G, Schneider P, Rohr U et al. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFα antibody. Bone Marrow Transplant.28(1), 47–49 (2001).
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N. Engl. J. Med.340(18), 1398–1405 (1999).
   PubMed Web of Science ®Google Scholar
• Couriel D, Saliba R, Hicks K et al. Tumor necrosis factor-α blockade for the treatment of acute GVHD. Blood104(3), 649–654 (2004).
   PubMed Web of Science ®Google Scholar
• Jacobsohn DA, Hallick J, Anders V, McMillan S, Morris L, Vogelsang GB. Infliximab for steroid-refractory acute GVHD: a case series. Am. J. Hematol.74(2), 119–124 (2003).
   PubMed Web of Science ®Google Scholar
• Nogueira MC, Azevedo AM, Pereira SC et al. Anti-tumor necrosis factor-α for the treatment of steroid-refractory acute graft-versus-host disease. Braz. J. Med. Biol. Res.40(12), 1623–1629 (2007).
   PubMed Web of Science ®Google Scholar
• Patriarca F, Sperotto A, Damiani D et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica89(11), 1352–1359 (2004).
   PubMed Web of Science ®Google Scholar
• Yamane T, Yamamura R, Aoyama Y et al. Infliximab for the treatment of severe steroid refractory acute graft-versus-host disease in three patients after allogeneic hematopoietic transplantation. Leuk. Lymphoma44(12), 2095–2097 (2003).
   PubMed Web of Science ®Google Scholar
• Marty FM, Lee SJ, Fahey MM et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood102(8), 2768–2776 (2003).
   PubMed Web of Science ®Google Scholar
• Wiens A, Correr CJ, Venson R, Grochocki MC, Otuki MF, Pontarolo R. A meta-analysis of the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis. Clin. Rheumatol.28(12), 1365–1373 (2009).
   PubMed Web of Science ®Google Scholar
• Couriel DR, Saliba R, de Lima M et al. A Phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. Biol. Blood Marrow Transplant.15(12), 1555–1562 (2009).
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med.340(4), 253–259 (1999).
   PubMed Web of Science ®Google Scholar
• Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? Clin. Infect. Dis.41(Suppl. 3), S199–S203 (2005).
   PubMed Web of Science ®Google Scholar
• Andolina M, Rabusin M, Maximova N, Di Leo G. Etanercept in graft-versus-host disease. Bone Marrow Transplant.26(8), 929 (2000).
   PubMed Web of Science ®Google Scholar
• Busca A, Locatelli F, Marmont F, Ceretto C, Falda M. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am. J. Hematol.82(1), 45–52 (2007).
   PubMed Web of Science ®Google Scholar
• Kennedy GA, Butler J, Western R, Morton J, Durrant S, Hill GR. Combination antithymocyte globulin and soluble TNFα inhibitor (etanercept) +/- mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease. Bone Marrow Transplant.37(12), 1143–1147 (2006).
   PubMed Web of Science ®Google Scholar
• Levine JE, Paczesny S, Mineishi S et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood111(4), 2470–2475 (2008).
   PubMed Web of Science ®Google Scholar
• Uberti JP, Ayash L, Ratanatharathorn V et al. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biol. Blood Marrow Transplant.11(9), 680–687 (2005).
   PubMed Web of Science ®Google Scholar
• Wolff D, Roessler V, Steiner B et al. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept. Bone Marrow Transplant.35(10), 1003–1010 (2005).
   PubMed Web of Science ®Google Scholar
• Perez-Simon JA, Encinas C, Silva F et al. Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy. Biol. Blood Marrow Transplant.14(10), 1163–1171 (2008).
   PubMed Web of Science ®Google Scholar
• Carlens S, Ringden O, Remberger M et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant.22(8), 755–761 (1998).
   PubMed Web of Science ®Google Scholar
• Pavletic SZ, Martin P, Lee SJ et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol. Blood Marrow Transplant.12(3), 252–266 (2006).
   PubMed Web of Science ®Google Scholar
• Martin PJ, Weisdorf D, Przepiorka D et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: VI. Design of Clinical Trials Working Group report. Biol. Blood Marrow Transplant.12(5), 491–505 (2006).
   PubMed Web of Science ®Google Scholar
• Chiang K-Y, Abhyankar S, Bridges K, Godder K, Henslee-Downey JP. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation73(4), 665–667 (2002).
   PubMed Web of Science ®Google Scholar
• Rodriguez V, Anderson PM, Trotz BA, Arndt CAS, Allen JA, Khan SP. Use of infliximab–daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut. Pediatr. Blood Cancer49(2), 212–215 (2007).
   PubMed Web of Science ®Google Scholar
• Sleight BS, Chan KW, Braun TM, Serrano A, Gilman AL. Infliximab for GVHD therapy in children. Bone Marrow Transplant.40(5), 473–480 (2007).
   PubMed Web of Science ®Google Scholar
• Teachey DT, Bickert B, Bunin N. Daclizumab for children with corticosteroid refractory graft-versus-host disease. Bone Marrow Transplant.37(1), 95–99 (2006).
   PubMed Web of Science ®Google Scholar
• Shapira MY, Abdul-Hai A, Resnick IB et al. Alefacept treatment for refractory chronic extensive GVHD. Bone Marrow Transplant.43(4), 339–343 (2009).
   PubMed Web of Science ®Google Scholar
• Stotler CJ, Eghtesad B, Hsi E, Silver B. Rapid resolution of GVHD after orthotopic liver transplantation in a patient treated with alefacept. Blood113(21), 5365–5366 (2009).
   PubMed Web of Science ®Google Scholar
• Ruiz-Arguelles GJ, Gil-Beristain J, Magana M, Ruiz-Delgado GJ. Alemtuzumab-induced resolution of refractory cutaneous chronic graft-versus-host disease. Biol. Blood Marrow Transplant.14(1), 7–9 (2008).
   PubMed Web of Science ®Google Scholar
• Zaja F, Russo D, Fuga G, Perella G, Baccarani M. Rituximab for myasthenia gravis developing after bone marrow transplantaton. Neurology55(7), 1062–1063 (2000).
   PubMed Web of Science ®Google Scholar
• Szabolcs P, Reese M, Yancey KB, Hall RP, Kurtzberg J. Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease. Bone Marrow Transplant.30(5), 327–329 (2002).
   PubMed Web of Science ®Google Scholar
• Ship A, May W, Lucas K. Anti-CD20 monoclonal antibody therapy for autoimmune hemolytic anemia following T cell-depleted, haplo-identical stem cell transplantation. Bone Marrow Transplant.29(4), 365–366 (2002).
   PubMed Web of Science ®Google Scholar
• Ratanatharathorn V, Ayash L, Reynolds C et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol. Blood Marrow Transplant.9(8), 505–511 (2003).
   PubMed Web of Science ®Google Scholar
• Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, Sanders CJ, van den Tweel JG, Verdonck LF. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood104(8), 2603–2606 (2004).
   PubMed Web of Science ®Google Scholar
• Cutler C, Miklos D, Kim HT et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood108(2), 756–762 (2006).
   PubMed Web of Science ®Google Scholar
• Okamoto M, Okano A, Akamatsu S et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia20(1), 172–173 (2006).
   PubMed Web of Science ®Google Scholar
• Carella AM, Biasco S, Nati S, Congiu A, Lerma E. Rituximab is effective for extensive steroid-refractory chronic graft-vs.-host-disease. Leuk. Lymphoma48(3), 623–624 (2007).
   PubMed Web of Science ®Google Scholar
• Zaja F, Bacigalupo A, Patriarca F et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant.40(3), 273–277 (2007).
   PubMed Web of Science ®Google Scholar
• Mohty M, Marchetti N, El-Cheikh J, Faucher C, Furst S, Blaise D. Rituximab as salvage therapy for refractory chronic GVHD. Bone Marrow Transplant.41(10), 909–911 (2008).
   PubMed Web of Science ®Google Scholar
• Teshima T, Nagafuji K, Henzan H et al. Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease. Int. J. Hematol.90(2), 253–260 (2009).
   PubMed Web of Science ®Google Scholar
• von Bonin M, Oelschlagel U, Radke J et al. Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab. Transplantation86(6), 875–879 (2008).
   PubMed Web of Science ®Google Scholar
• Martin PJ, Bachier CR, Klingemann HG et al. Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement. Biol. Blood Marrow Transplant.15(7), 777–784 (2009).
   PubMed Web of Science ®Google Scholar
• Macmillan ML, Defor TE, Weisdorf DJ. The best endpoint for acute GVHD treatment trials. Blood115(26), 5412–5417 (2010).
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, Cutler C, Mohty M, Kumar A. Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biol. Blood Marrow Transplant.15(9), 1005–1013 (2009).
   PubMed Web of Science ®Google Scholar
• Benson DM Jr, Smith MK, Krugh D, Devine SM. Successful therapy of chronic graft-versus-host disease manifesting as pure red cell aplasia with single-agent rituximab. Bone Marrow Transplant.41(6), 595–596 (2008).
   PubMed Web of Science ®Google Scholar